Nephrology
China approves fruquintinib combination for kidney cancer
May 29, 2026Kidney cancer, Nephrology
China’s National Medical Products Administration (NMPA) has approved a combination of ELUNATE (fruquintinib) and TYVYT (sintilimab) for patients with advanced …
Sobi’s Aspaveli receives European Commission approval for treatment of two rare kidney diseases
January 28, 2026Aspaveli, European Commission, Nephrology, sobi
Sobi has announced that its Aspaveli (pegcetacoplan) has received approval from the European Commission (EC) for the treatment of two …
Evotec and Bayer announce new kidney disease study
December 11, 2025Research and Development Bayer, Evotec, Nephrology
Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney disease, stemming from their previous …
SphingoTec’s PenKid leads the way in early detection of delayed graft function after kidney transplant
July 1, 2025Medical Communications, Research and Development Nephrology, PenKid, SphingoTec, biomarker, clinical trial, delayed graft function, kidney replacement therapy, kidney transplant, serum creatinine
SphingoTec has announced new findings validating the clinical utility of its kidney biomarker proenkephalin A 119-159 (PenKid) in assessing graft …
Opterion Health strengthens board with appointments of Rice Powell and Mark Hahn
June 25, 2025Research and Development CEO, Nephrology, Opterion Health, board of directors, cfo, chronic kidney disease, dialysis solution
Swiss life sciences company Opterion Health has appointed two senior industry figures to its board of directors: Rice Powell, former …
Takeda presents positive results from trial of chronic kidney disease treatment
June 10, 2025Research and Development European Renal Association, Immunology, Nephrology, Takeda, autoimmune disease, immunoglobulin A nephropathy (IgAN), kidney disease
Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat patients with primary immunoglobulin A …
NIPRO introduces LiniXia water treatment system for dialysis clinics
June 4, 2025Research and Development European Renal Association (ERA) Congress, LiniXia, LiniXia PRO, NIPRO, Nephrology, dialysis clinics, water treatment
Japan-based biopharma, NIPRO, has launched LiniXia, a new reverse osmosis (RO) water treatment system for haemodialysis. It was unveiled at …
NICE recommends treatment for chronic kidney disease, IgA nephropathy
May 23, 2025Market & Product Development, Medical Communications, Research and Development IgA nephropathy, National Institute for Health and Care Excellence, Nephrology, kidney disease
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending CSL Vifor’s FILSPARI (sparsentan) for …
EU approval granted for rare kidney disease treatment
April 29, 2025Market Access, Research and Development, Sales and Marketing CSL Vifor, EU, Nephrology, Travere Therapeutics, kidney disease, nephrology
The EU has granted marketing authorisation (MA) for Filspari – CSL Vifor and Travere Therapeutics’ therapy for primary IgA nephropathy …
Kidney Research UK backs digital innovation to support 15 million patients with long-term conditions
April 22, 2025Medical Education, Patient Awareness Programmes, Public Relations Cognitant Group, Kidney Research UK, Nephrology, chronic kidney disease (CKD)
Kidney Research UK has announced an ambitious investment in the patient engagement platform Healthinote, developed by Cognitant Group, in a …
VALIANT phase 3 trial results highlight potential treatment for rare kidney diseases
October 25, 2024Nephrology, Rare Diseases, rare kidney disease, trial
SOBI and Apellis Pharmaceuticals have announced the results from the VALIANT trial, which highlight that systemic pegcetacoplan treatment could benefit …
China’s NMPA accepts Everest Medicines’ Nefecon supplementary application
July 18, 2024Medical Communications China, Everest Medicines, NMPA, Nephrology
Everest Medicines has announced that China’s National Medical Products Administration (NMPA) has accepted the submission of a supplemental New Drug …
Renalys Pharma closes ¥6bn series A financing for kidney disease treatments in Asia
July 17, 2024Business Services Financing, Nephrology, kidney disease, renalys Pharma
Renalys Pharma has announced that it has completed ¥6bn series A financing, which was led by Catalys Pacific and SR …
Novartis shares new data about Fabhalta for IgAN treatment
April 16, 2024Research and Development Fabhalta, IgAN, Nephrology, Novartis, nephropathy
Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN trial of Fabhalta (iptacopan), an …
Vertex to acquire Alpine Immune Sciences for $4.9bn
April 11, 2024Business Services Alpine Immune Sciences, Nephrology, Vertex pharmaceuticals, acquisition, nephropathy
Vertex Pharmaceuticals and Alpine Immune Sciences have announced that they have entered into a definitive agreement under which Vertex will …
Latest content
FibroFind appoints Lee Borthwick as CEO
